Clinicopathologic analysis of nodal T-follicular helper cell lymphomas, a multicenter retrospective study from China

Front Immunol. 2024 Mar 27:15:1371534. doi: 10.3389/fimmu.2024.1371534. eCollection 2024.

Abstract

Background: Nodal T-follicular helper cell lymphomas (nTFHLs) represent a new family of peripheral T-cell lymphomas (PTCLs), and comparative studies of their constituents are rare.

Methods: This study retrospectively enrolled 10 patients with nTFHL-F and 30 patients with nTFHL-NOS diagnosed between December 2017 and October 2023 at six large comprehensive tertiary hospitals; 188 patients with nTFHL-AI were diagnosed during the same period at the First Affiliated Hospital of Zhengzhou University for comparison.

Results: Compared with nTFHL-AI, nTFHL-NOS patients exhibited better clinical manifestations, lower TFH expression levels, and a lower Ki-67 index. However, no differences in clinicopathological features were observed between nTFHL-F and nTFHL-AI patients as well as nTFHL-NOS patients. According to the survival analysis, the median OS for patients with nTFHL-NOS, nTFHL-AI, and nTFHL-F were 14.2 months, 10 months, and 5 months, respectively, whereas the median TTP were 14 months, 5 months, and 3 months, respectively. Statistical analysis revealed differences in TTP among the three subtypes(P=0.0173). Among the population of patients receiving CHOP-like induction therapy, there were significant differences in the OS and TTP among the nTFHL-NOS, nTFHL-AI, and nTFHL-F patients (P=0.0134, P=0.0205). Both the GDPT and C-PET regimens significantly improved the ORR, OS, and PFS in nTFHL patients.

Conclusion: There are significant differences in the clinical manifestations, pathology, and survival outcomes among the three subtypes of nTFHLs. However, further research with a larger sample size, and involving clinical pathology and molecular genetics is needed to determine the distinctive biological characteristics of these tumors.

Keywords: clinical features; clinicopathology; nodal T-follicular helper cell lymphoma; peripheral T-cell lymphoma; prognostic analysis.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • China / epidemiology
  • Humans
  • Lymphoma, T-Cell, Peripheral* / drug therapy
  • Retrospective Studies
  • Survival Analysis
  • T-Lymphocytes, Helper-Inducer / metabolism

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This study was supported by National Nature Science Foundation of China (Grant No.81970184, No.82170183, No.82070209).